Cargando…
Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
SIMPLE SUMMARY: Multiple myeloma is an incurable hematologic malignancy arising from terminally differentiated B-cells. Over the last decade, advancements in therapeutics have radically shifted the treatment landscape of MM, significantly improving the survival of patients. In this review, we will d...
Autores principales: | Dima, Danai, Ullah, Fauzia, Mazzoni, Sandra, Williams, Louis, Faiman, Beth, Kurkowski, Austin, Chaulagain, Chakra, Raza, Shahzad, Samaras, Christy, Valent, Jason, Khouri, Jack, Anwer, Faiz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093129/ https://www.ncbi.nlm.nih.gov/pubmed/37046821 http://dx.doi.org/10.3390/cancers15072160 |
Ejemplares similares
-
Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma
por: Chaulagain, Chakra P, et al.
Publicado: (2022) -
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021) -
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020) -
Risk of Venous Thromboembolism
in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase
por: Awada, Hussein, et al.
Publicado: (2023) -
Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients
por: Chaulagain, Chakra P., et al.
Publicado: (2020)